You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雅各臣科研製藥(02633.HK)年度純利減少約19.4%至1.74億港元 末期息1.5港仙
格隆匯 06-29 22:53

格隆匯6月29日丨雅各臣科研製藥(02633.HK)發佈公吿,截至2021年3月31日止年度,公司收益約為14.46億港元,同比減少約8.0%;經營溢利約為2.56億港元,同比減少約19.5%;公司權益持有人應占溢利約為1.74億港元,同比減少約19.4%,末期股息每股1.5港仙。

產品研發於報吿期內進展順利。皮膚病學、胃腸病學及內分泌學領域的共4項產品已成功註冊,並準備於香港推出。包括氟哌啶醇美沙拉秦(Haloperodol Mesalazine)及加巴噴丁(Gabapentin)在內的另外五項新產品已完成開發過程,並已提交香港衞生署以待審批。

此外,於報吿期內,公司新增7個研發項目。於2021年3月31日,公司正在研發的158項產品處於不同開發及註冊階段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account